- Home
- CRAC vs EDIT Comparison
CRAC vs EDIT Comparison
Compare CRAC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRAC | EDIT |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | | |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.0M | 206.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CRAC | EDIT |
|---|---|---|
| Price | $10.00 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 40.6K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $0.91 |
| 52 Week High | $10.05 | $4.54 |
Technical Indicators
Market Signals| Indicator | CRAC | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 38.39 |
| Support Level | $9.97 | $1.67 |
| Resistance Level | $10.02 | $1.83 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 37.50 | 15.22 |
Price Performance
Historical ComparisonAbout CRAC Crown Reserve Acquisition Corp. I Class A Ordinary Shares
Crown Reserve Acquisition Corp I is a blank check company.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.